HIGHLIGHTS
- who: Martina Catalano and collaborators from the School of Human Health Sciences, University of Florence, Florence, Italy have published the paper: Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors, in the Journal: Cancers 2022, 14, 6145. of /2022/
- what: The analysis showed a satisfying safety profile and an improved ORR (31.3 vs. 16.2%) and PFS (5.4 vs. 3.6 months) in the combination treatment with durable responses particularly in patients with a PD-L1 expression score >50%.
- how: Drug combinations targeting both TIM-3 and PD-L1 immune checkpoint pathways . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.